National Academies of Sciences Engineering and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington: The National Academies Press; 2017.
Google Scholar
Cascio MG, Pertwee RG, Marini P. The pharmacology and therapeutic potential of plant cannabinoids. In: Chandra, S, Lata H, ElSohly MA, editors. Cannabis sativa L.-Botany and Biotechnology. Springer; 2017. p. 207–225.
Grotenhermen F, Müller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int. 2012;109(29–30):495.
PubMed
PubMed Central
Google Scholar
Cohen K, Weizman A, Weinstein A. Positive and negative effects of cannabis and cannabinoids on health. Clin Pharmacol Ther. 2019;105(5):1139–47.
Article
PubMed
Google Scholar
Taylor S. Re-medicalizing cannabis: science, medicine and policy, 1973 to the early twenty-first century. London: London School of Hygiene & Tropical Medicine; 2010.
Google Scholar
Taylor S. Medicalizing cannabis—Science, medicine and policy, 1950–2004: An overview of a work in progress. Drugs Educ Prev Policy. 2009;15(5):462–74.
Article
Google Scholar
National Conference of State Legislatures State Medical Marijuana Laws. National Conference of State Legislatures. 2020 [cited 2020 Mar 30]. Available from: http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx.
Castle DJ, et al. Medical marijuana: the Australian experience. Mo Med. 2019;116(4):270.
PubMed
PubMed Central
Google Scholar
Fischer B, Kuganesan S, Room R. Medical Marijuana programs: implications for cannabis control policy–observations from Canada. Int J Drug Policy. 2015;26(1):15–9.
Article
PubMed
Google Scholar
Abuhasira R, Shbiro L, Landschaft Y. Medical use of cannabis and cannabinoids containing products—regulations in Europe and North America. Eur J Intern Med. 2018;49:2–6.
Article
PubMed
Google Scholar
Kvamme SL, et al. Beyond the high: mapping patterns of use and motives for use of cannabis as medicine. Nordic Stud Alcohol Drugs. 2021;38:270–92.
Article
Google Scholar
D’Souza DC, Ranganathan M. Medical marijuana: is the cart before the horse? JAMA. 2015;313(24):2431–2.
Article
CAS
PubMed
Google Scholar
Fletcher J. Marijuana is not a prescription medicine. Can Med Assoc J. 2013;185(5):369.
Article
Google Scholar
Collen M. Prescribing cannabis for harm reduction. Harm Reduct J. 2012;9(1):1.
Article
PubMed
PubMed Central
Google Scholar
Corroon J. Medical Cannabis: An Antidote to the Opioid Epidemic? 2017 Nov 1. 2017 17.02.2020]. https://www.centerformedicalcannabis.com/post/2017/11/01/medical-cannabis-an-antidote-to-the-opioid-epidemic.
Hurd YL. Cannabidiol: swinging the marijuana pendulum from ‘weed’to medication to treat the opioid epidemic. Trends Neurosci. 2017;40(3):124–7.
Article
CAS
PubMed
Google Scholar
Lucas P. Rationale for cannabis-based interventions in the opioid overdose crisis. Harm Reduct J. 2017;14(1):58.
Article
PubMed
PubMed Central
Google Scholar
Noble F, Marie N. Management of opioid addiction with opioid substitution treatments: beyond methadone and buprenorphine. Front Psychiatry. 2019. https://doi.org/10.3389/fpsyt.2018.00742.
Article
PubMed
PubMed Central
Google Scholar
Sordo L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. Br Med J. 2017. https://doi.org/10.1136/bmj.j1550.
Article
Google Scholar
Hursh SR, et al. The economics of drug abuse: a quantitative assessment of drug demand. Mol Interv. 2005;5(1):20.
Article
PubMed
Google Scholar
Fareed A, et al. Effect of methadone maintenance treatment on heroin craving, a literature review. J Addict Dis. 2010;30(1):27–38.
Article
Google Scholar
Room R. Smoking and drinking as complementary behaviours. Biomed Pharmacother. 2004;58(2):111–5.
Article
PubMed
Google Scholar
Sumnall HR, et al. A behavioural economic analysis of alcohol, amphetamine, cocaine and ecstasy purchases by polysubstance misusers. Drug Alcohol Depend. 2004;76(1):93–9.
Article
PubMed
Google Scholar
Lucas P, Baron EP, Jikomes N. Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients. Harm Reduct J. 2019;16(1):9.
Article
PubMed
PubMed Central
Google Scholar
Lucas P, et al. Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: the impact of contextual factors. Drug Alcohol Rev. 2016;35(3):326–33.
Article
PubMed
Google Scholar
Piper BJ, et al. Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. J Psychopharmacol. 2017;31(5):569–75.
Article
PubMed
Google Scholar
Reiman A, Welty M, Solomon P. Cannabis as a substitute for opioid-based pain medication: patient self-report. Cannabis Cannabinoid Res. 2017;2(1):160–6.
Article
PubMed
PubMed Central
Google Scholar
Boehnke KF, et al. Pills to pot: observational analyses of cannabis substitution among medical cannabis users with chronic pain. J Pain. 2019;20(7):830–41.
Article
PubMed
Google Scholar
Corroon JM, Mischley LK, Sexton M. Cannabis as a substitute for prescription drugs–a cross-sectional study. J Pain Res. 2017;10:989.
Article
PubMed
PubMed Central
Google Scholar
Lucas P, et al. Cannabis as a substitute for alcohol and other drugs: a dispensary-based survey of substitution effect in Canadian medical cannabis patients. Addict Res Theory. 2013;21(5):435–42.
Article
Google Scholar
Lau N, et al. A safer alternative: cannabis substitution as harm reduction. Drug Alcohol Rev. 2015;34(6):654–9.
Article
PubMed
Google Scholar
Bradford AC, Bradford WD. Medical marijuana laws reduce prescription medication use in medicare part D. Health Aff. 2016;35(7):1230–6.
Article
Google Scholar
Bradford AC, et al. Association between US state medical cannabis laws and opioid prescribing in the medicare part D population. JAMA Intern Med. 2018;178(5):667–72.
Article
PubMed
PubMed Central
Google Scholar
Wen H, Hockenberry JM. Association of medical and adult-use marijuana laws with opioid prescribing for Medicaid enrollees. JAMA Intern Med. 2018;178(5):673–9.
Article
PubMed
PubMed Central
Google Scholar
Vigil JM, et al. Associations between medical cannabis and prescription opioid use in chronic pain patients: a preliminary cohort study. PLoS ONE. 2017;12(11):e0187795.
Article
PubMed
PubMed Central
CAS
Google Scholar
Vyas MB, LeBaron VT, Gilson AM. The use of cannabis in response to the opioid crisis: a review of the literature. Nurs Outlook. 2018;66(1):56–65.
Article
PubMed
Google Scholar
Gross T, Laugesen MJ. The price of health care: why is the United States an outlier? J Health Polit Policy Law. 2018;43(5):771–91.
Article
Google Scholar
Dickman SL, Himmelstein DU, Woolhandler S. Inequality and the health-care system in the USA. The Lancet. 2017;389(10077):1431–41.
Article
Google Scholar
EMCDDA, Italy’s highest court says low-THC cannabis cannot be sold; 2019 [cited 2020 Nov 01]. Available from: https://www.emcdda.europa.eu/news/2019/italy-and-sweden-court-decisions-low-thc-cannabis-products_en.
Carrieri V, Madio L, Principe F. Do-It-Yourself medicine? The impact of light cannabis liberalization on prescription drugs. J Health Econ. 2020;74:102371.
Article
PubMed
Google Scholar
Rømer Thomsen K, Callesen MB, Ewing SWF. Recommendation to reconsider examining cannabis subtypes together due to opposing effects on brain, cognition and behavior. Neurosci Biobehav Rev. 2017;80:156–8.
Article
PubMed
Google Scholar
Englund A, et al. Can we make cannabis safer? The Lancet Psychiatry. 2017;4(8):643–8.
Article
PubMed
Google Scholar
Iseger TA, Bossong MG. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res. 2015;162(1–3):153–61.
Article
PubMed
Google Scholar
Bonaccorso S, et al. Cannabidiol (CBD) use in psychiatric disorders: a systematic review. Neurotoxicology. 2019;74:282–98.
Article
CAS
PubMed
Google Scholar
Blessing EM, et al. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015;12(4):825–36.
Article
CAS
PubMed
PubMed Central
Google Scholar
Prud’homme M, Cata R, Jutras-Aswad D. Cannabidiol as an intervention for addictive behaviors: a systematic review of the evidence. Subst Abuse Res Treat. 2015;9:SART. S25081.
Article
Google Scholar
Freeman TP, et al. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. The Lancet Psychiatry. 2020;7(10):865–74.
Article
PubMed
PubMed Central
Google Scholar
Freeman AM, et al. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neurosci Biobehav Rev. 2019;107:696–712.
Article
CAS
PubMed
Google Scholar
Wiese B, Wilson-Poe AR. Emerging evidence for cannabis’ role in opioid use disorder. Cannabis Cannabinoid Res. 2018;3(1):179–89.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kosiba JD, Maisto SA, Joseph W. Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: systematic review and meta-analysis. Social Sci Med. 2019;233:181–92.
Article
Google Scholar
MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12–9.
Article
CAS
PubMed
Google Scholar
Gable RS. Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction. 2004;99(6):686–96.
Article
PubMed
Google Scholar
Grotenhermen F. Review of unwanted actions of cannabis and THC. In: Grotenhermen F, Russo E, editors. Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. Haworth Press; 2002; p. 233–248.
Larkin PJ Jr, Madras BK. Opioids, overdoses, and cannabis: is marijuana an effective therapeutic response to the opioid abuse epidemic. Georget J Law Public Policy. 2019;17:555.
Google Scholar
Nielsen S, et al. Opioid-sparing effect of cannabinoids: a systematic review and meta-analysis. Neuropsychopharmacology. 2017;42(9):1752–65.
Article
CAS
PubMed
PubMed Central
Google Scholar
Voelker R. States move to substitute opioids with medical marijuana to quell epidemic. JAMA. 2018;320(23):2408–10.
Article
PubMed
Google Scholar
Zolotov Y, et al. Medical cannabis: an oxymoron? Physicians’ perceptions of medical cannabis. Int J Drug Policy. 2018;57:4–10.
Article
PubMed
Google Scholar
Campbell G, et al. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Health. 2018;3(7):e341–50.
Article
PubMed
PubMed Central
Google Scholar
Hall W, et al. It is premature to expand access to medicinal cannabis in hopes of solving the US opioid crisis. Addiction. 2018;113(6):987–8.
Article
PubMed
Google Scholar
Humphreys K, Saitz R. Should physicians recommend replacing opioids with cannabis? JAMA. 2019;321(7):639–40.
Article
PubMed
Google Scholar
Shover CL, et al. Association between medical cannabis laws and opioid overdose mortality has reversed over time. Proc Natl Acad Sci USA. 2019;116(26):12624–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nugent SM, et al. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med. 2017;167(5):319–31.
Article
PubMed
Google Scholar
Olfson M, et al. Cannabis use and risk of prescription opioid use disorder in the United States. Am J Psychiatry. 2018;175(1):47–53.
Article
PubMed
Google Scholar
Lucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients. Int J Drug Policy. 2017;42:30–5.
Article
PubMed
Google Scholar
Ministry of Health. Aftale om forsøgsordning med medicinsk cannabis (Agreement on medical cannabis pilot programme). 2016 8 nov [cited 2020 30.03.]. http://sundhedsministeriet.dk/Aktuelt/Nyheder/Medicin/2016/November/~/media/Filer%20-%20dokumenter/Aftale-om-medicinsk-cannabis/Politisk-aftale-om-forsogsordning-med-medicinsk-cannabis.ashx.
Damløv L. Cannabis-sælgere på nettet vildleder syge mennesker [Cannabis sellers on the internet mislead sick people]. In: Danmarks Radio 2016. [cited 2021 April 1]. Available from: https://www.dr.dk/nyheder/indland/cannabis-saelgere-paa-nettet-vildleder-syge-mennesker.
Færch M. Pusherstreet er blevet et alternativt lægehus [Pusherstreet has become an alternative doctors office]. In: Information: 2013. [cited 2021 April 1]. Available from: Pusherstreet er blevet et alternativt lægehus | Information.
Sørensen LD, Skaaning J. Politi og SKAT beslaglægger mere cannabisolie [Police and costums seize more cannabsi oil]. In: Danmarks Radio 2017. [cited 2021 April 1]. Available from: https://www.dr.dk/nyheder/indland/politi-og-skat-beslaglaegger-mere-cannabisolie.
Lægemiddelstyrelsen, Change of the THC limit as of 1 July 2018. 2018. [cited 2021 April 1]. Available from: https://laegemiddelstyrelsen.dk/en/special/medicinal-cannabis/citizens/change-of-the-thc-limit-as-of-1-july-2018/.
Sundhedsstyrelsen (Danish Health Authority). Kortlægning af opioidforbruget i Danmark (Mapping of opioid consumotion in Denmark). 2016 [cited 2020 22.03]. https://www.sst.dk/-/media/Udgivelser/2016/KortlaegningOpioidforbrugetiDanmark2016.ashx?la=da&hash=E4C4C84EA5D5D378F23CAEFC3AD096358A84BE3B.
Dahl HV, Frank VA. Medical marijuana–exploring the concept in relation to small scale cannabis growers in Denmark. In: Decorte T, Potter G, Bouchard M, editors. World wide weed–global trends in cannabis cultivation and its control. Routledge; 2011; p. 116–141.
Dahl HV. Ilde hørt?: Den larmende tavshed om etnografisk rusmiddelforskning [Uncomfortable truths? The alarming silence of ethnographic intoxicant research]. In: Asmussen V, Jöhncke S, editors. Brugerperspektiver. Aarhus: Aarhus Universitetsforlag; 2004. p. 39–71.
Google Scholar
Khan SP, Pickens TA, Berlau DJ. Perspectives on cannabis as a substitute for opioid analgesics. Pain Manag. 2019;9(2):191–203.
Article
PubMed
Google Scholar
Grotenhermen F, Schnelle M. Survey on the medical use of cannabis and THC in Germany. J Cannabis Ther. 2003;3(2):17–40.
Article
Google Scholar
Ware M, Adams H, Guy G. The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract. 2005;59(3):291–5.
Article
CAS
PubMed
Google Scholar
Reinarman C, et al. Who are medical marijuana patients? Population characteristics from nine California assessment clinics. J Psychoact Drugs. 2011;43(2):128–35.
Article
Google Scholar
Hazekamp A, et al. The medicinal use of cannabis and cannabinoids–an international cross-sectional survey on administration forms. J Psychoact Drugs. 2013;45(3):199–210.
Article
Google Scholar
Webb CW, Webb SM. Therapeutic benefits of cannabis: a patient survey. Hawai’i J Med Public Health. 2014;73(4):109.
Google Scholar
Sexton M, et al. A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy. Cannabis Cannabinoid Res. 2016;1(1):131–8.
Article
PubMed
PubMed Central
Google Scholar
Barratt MJ, et al. Moving on from representativeness: testing the utility of the global drug survey. Subst Abuse Res Treat. 2017;11:1–17.
Google Scholar
Hamilton LC. Statistics with Stata: version 12. Boston: Cengage Learning; 2012.
Google Scholar
Bazeley P, Jackson K. Qualitative data analysis with NVivo. Thousand Oaks: SAGE Publications Limited; 2013.
Google Scholar
Fay MP, Proschan MA. Wilcoxon–Mann–Whitney or t-test? On assumptions for hypothesis tests and multiple interpretations of decision rules. Stat Surv. 2010;4:1.
Article
PubMed
PubMed Central
Google Scholar
Baron EP, et al. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. J Headache Pain. 2018;19(1):37.
Article
PubMed
PubMed Central
Google Scholar
Troutt WD, DiDonato MD. Medical cannabis in Arizona: patient characteristics, perceptions, and impressions of medical cannabis legalization. J Psychoactive Drugs. 2015;47(4):259–66.
Article
PubMed
Google Scholar
Cuttler C, Mischley LK, Sexton M. Sex differences in cannabis use and effects: a cross-sectional survey of cannabis users. Cannabis Cannabinoid Res. 2016;1(1):166–75.
Article
PubMed
PubMed Central
Google Scholar
Bottorff JL, et al. Health effects of using cannabis for therapeutic purposes: a gender analysis of users’ perspectives. Subst Use Misuse. 2011;46(6):769–80.
Article
PubMed
Google Scholar
Konkurrence- og Forbrugerstyrelsen (Danish Competition and Consumer Authority). Priscykler i markedet of receptpligtig medicin efter patentudløb (Price cycles in the market of prescription drugs after patent expiration). 2017 [cited 2020 06.09]. https://www.kfst.dk/media/49083/priscykler-i-markedet-for-receptpligtig-medicin-efter-patentudloeb_final.pdf.
Lægemiddelstyrelsen (Danish Medicines Agency). Accessibility strategy for the Danish Medicines Agency (Tilgængelighedsstrategi for Lægemiddelstyrelsen). 2019 dec [cited 2020 08.09.]. https://laegemiddelstyrelsen.dk/da/om/mission-og-vision/~/media/198CC9D5130E4AA1B3555E2D8ACCA7E7.ashx.
Lægemiddelstyrelsen (Danish Medicines Agency). Refusionstærskler (Reimbursement thresholds). 2020 [cited 2020 22.09.]. https://laegemiddelstyrelsen.dk/en/reimbursement/calculate-reimbursement/reimbursement-thresholds/.
Harker J, et al. Epidemiology of chronic pain in Denmark and Sweden. Pain Res Treat. 2012. https://doi.org/10.1155/2012/371248.
Article
PubMed
PubMed Central
Google Scholar
Dansk Psykolog Forening (Danish Psychological Association). Indstilling af kroniske non-maligne smerter som emne til lærings-og kvalitetsteams (LKT) (Suggestion of non-malignant pain as a topic for learning- and qualityteams (LKT)). 2017 [cited 2020 07.09.]. https://www.dp.dk/wp-content/uploads/indstilling-af-kroniske-nonmaligne-smerter-til-laerings-og-kvalitetsteams-danske-regioner_5224445.pdf.
Lægemiddelstyrelsen (Danish Medicines Agency). Bivirkningsindberetninger om afhængighed ved tramadol (Adverse reaction reports on tramadol dependence). 20.12.2020 [cited 2020 22.03.]. https://laegemiddelstyrelsen.dk/da/nyheder/2018/ny-rapport-om-bivirkningsindberetninger-om-den-smertestillende-medicin-tramadol/~/media/EA458B367F9B47769FA0A860D8DF10A5.ashx.
Sundhedsdatastyrelsen (Danish Health Data Autority). Færre langtidsbrugere af opoider i 2017 (Fewer longterm users of opioids in 2017). 2018 [cited 2020 06.09.]. https://sundhedsdatastyrelsen.dk/da/nyheder/2018/faerrre_langtidsbrugere_af_opioider_2017_24082018.
Sundhedsdatastyrelsen (Danish Health Data Authority). Antallet af brugere af tramadol falder med 23 procent (The number of tramadol users has fallen by 23 percent). 05.04.2019 [cited 2020 08.09]. https://sundhedsdatastyrelsen.dk/da/nyheder/2019/tramadol_05042019.
Choo EK, Ewing SWF, Lovejoy TI. Opioids out, cannabis in: negotiating the unknowns in patient care for chronic pain. JAMA. 2016;316(17):1763–4.
Article
PubMed
PubMed Central
Google Scholar
Corroon J, Phillips JA. A cross-sectional study of cannabidiol users. Cannabis Cannabinoid Res. 2018;3(1):152–61.
Article
CAS
PubMed
PubMed Central
Google Scholar
Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res. 2017;2(1):139–54.
Article
CAS
PubMed
PubMed Central
Google Scholar
Colizzi M, Bhattacharyya S. Does cannabis composition matter? Differential effects of delta-9-tetrahydrocannabinol and cannabidiol on human cognition. Curr Addict Rep. 2017;4(2):62–74.
Article
PubMed
PubMed Central
Google Scholar
Chesney E et al. Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology 2020: p. 1–8.
Hazekamp A. The trouble with CBD oil. Med Cannabis Cannabinoids. 2018;1(1):65–72.
Article
PubMed
PubMed Central
Google Scholar
Lenton S, et al. Growing practices and the use of potentially harmful chemical additives among a sample of small-scale cannabis growers in three countries. Drug Alcohol Depend. 2018;192:250–6.
Article
CAS
PubMed
Google Scholar
Eriksen T, Christoffersen DJ. Har du også indtaget cannabis uden at vide det? (Have you also ingested cannabis without knowing it?). 2020 19.08.2020 [cited 2020 10.10.]. https://videnskab.dk/forskerzonen/krop-sundhed/har-du-ogsaa-indtaget-cannabis-uden-at-vide-det.
Freeman T, et al. Increasing potency and price of cannabis in Europe, 2006–16. Addiction. 2019;114(6):1015–23.
Article
PubMed
PubMed Central
Google Scholar
ElSohly MA, et al. Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol Psychiat. 2016;79(7):613–9.
Article
CAS
PubMed
Google Scholar
Smart R, et al. Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. Addiction. 2017;112(12):2167–77.
Article
PubMed
PubMed Central
Google Scholar
Rømer Thomsen K, et al. Changes in the composition of cannabis from 2000–2017 in Denmark: analysis of confiscated samples of cannabis resin. Exp Clin Psychopharmacol. 2019;27(4):402–11.
Article
PubMed
CAS
Google Scholar
Freeman T, Winstock A. Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med. 2015;45(15):3181–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Curran HV, et al. Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects? Psychol Med. 2019;49(9):1574–80.
Article
PubMed
Google Scholar
Freeman TP, et al. Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in the Netherlands. Psychol Med. 2018;48(14):2346–52.
Article
PubMed
Google Scholar
Di Forti M, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. The Lancet Psychiatry. 2019;6(5):427–36.
Article
PubMed
PubMed Central
Google Scholar
Di Forti M, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 2014;40(6):1509–17.
Article
PubMed
Google Scholar
Morgan CJ, et al. Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry. 2018;8(1):1–10.
Article
CAS
Google Scholar
Freeman TP, et al. Just say ‘know’: how do cannabinoid concentrations influence users’ estimates of cannabis potency and the amount they roll in joints? Addiction. 2014;109(10):1686–94.
Article
PubMed
Google Scholar
van der Pol P, et al. Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. Addiction. 2014;109(7):1101–9.
Article
PubMed
Google Scholar
Carrieri V, Madio L, Principe F. Light cannabis and organized crime: Evidence from (unintended) liberalization in Italy. Eur Econ Rev. 2019;113:63–76.
Article
Google Scholar
Barratt MJ, Ferris JA, Lenton S. Hidden populations, online purposive sampling, and external validity: Taking off the blindfold. Field Methods. 2015;27(1):3–21.
Article
Google Scholar
Althubaiti A. Information bias in health research: definition, pitfalls, and adjustment methods. J Multidiscip Healthc. 2016;9:211.
Article
PubMed
PubMed Central
Google Scholar
Ochayon L, Spiro H, Kadmon I. Expectations versus reality: improvement of symptom control and quality of life of oncology patients using medical cannabis. Clin J Nurs Care Pract. 2020;4:027.
Article
Google Scholar
Qian Y, Gurley BJ, Markowitz JS. The potential for pharmacokinetic interactions between cannabis products and conventional medications. J Clin Psychopharmacol. 2019;39(5):462–71.
Article
CAS
PubMed
Google Scholar
Brown JD. Potential adverse drug events with tetrahydrocannabinol (THC) due to drug–drug interactions. J Clin Med. 2020;9(4):919.
Article
CAS
PubMed Central
Google Scholar